Are randomized, blind clinical trials enough to guide individualized decisions for patients with neurologic diseases?

Neurology: Clinical Practice

Volumn 4, Issue 4, 2014, Pages 319-328

  Alderazi, Yazan J ^a   Bomprezzi, Roberto ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Maine General Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; DOCTOR PATIENT RELATION; EVIDENCE BASED MEDICINE; HUMAN; INFORMATION PROCESSING; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATIENT CARE; PATIENT DECISION MAKING; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

EID: 84925873444     PISSN: 21630402     EISSN: 21630933     Source Type: Journal    
DOI: 10.1212/CPJ.0000000000000046     Document Type: Article

References (24)

1. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-72.
2. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
3. Jane-wit D, Horwitz RI, Concato J. Variation in results from randomized, controlled trials: stochastic or systematic? J Clin Epidemiol 2010;63:56-63.
4. Ioannidis JP, Haidich AB, Pappa M, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001;286:821-830.
5. Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003;61:184-189.
6. Gholipour T, Healy B, Baruch NF, Weiner HL, Chitnis T. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology 2011;76:1996-2001.
7. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991;29:548-555.
8. Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage. Neurology 2008;71 (suppl 3):S3-S7.
9. Goodin DS. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology 2008;71(suppl 3):S8-S13.
10. Coyle PK. Switching algorithms: from one immunomodulatory agent to another. J Neurol 2008;255 (suppl 1):44-50.
11. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308:247-256.
12. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA 2007;298:1209-1212.
13. Vandenbroeck K, Comabella M. Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis. J Interferon Cytokine Res 2010;30:727-732.
14. Hesse D, Krakauer M, Lund H, et al. Breakthrough disease during interferon-[beta] therapy in MS: no signs of impaired biologic response. Neurology 2010;74:1455-1462.
15. Biogen Idec. Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS). Available at: http://clinicaltrials.gov/ct2/show/NCT01058005. Accessed November 9, 2012.
16. Castillo-Trivino T, Mowry EM, Gajofatto A, et al. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One 2011;6:e16664.
17. Hurwitz BJ. Analysis of current multiple sclerosis registries. Neurology 2011;76(suppl 1):S7-S13.
18. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study: HAEST Study Group: Heparin in Acute Embolic Stroke Trial. Lancet 2000;355:1205-1210.
19. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400-406.
20. Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011;76:2017-2023.
21. Voeks JH, Howard G, Roubin GS, et al. Age and outcomes after carotid stenting and endarterectomy: the Carotid Revascularization Endarterectomy versus Stenting Trial. Stroke 2011;42:3484-3490.
22. Lyden PD, Meyer BC, Hemmen TM, Rapp KS. An ethical hierarchy for decision making during medical emergencies. Ann Neurol 2010;67:434-440.
23. Zaidat OO, Klucznik R, Alexander MJ, et al. The NIH registry on use of the Wingspan stent for symptomatic 70-99% intracranial arterial stenosis. Neurology 2008;70:1518-1524.
24. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011;365:993-1003.